无症状重度主动脉瓣狭窄保留射血分数患者纵向SAVR结局
共17,683例,无症状者1,399例(7.9%)。风险调整后无症状组10年生存优于有症状组(aHR 1.19,95%CI 1.09-1.29)。
要点
- 无症状重度AS且LVEF≥50%行SAVR者长期生存优于有症状者。
- 年龄≥75岁、LVEF≥60%、STS PROM<2%亚组中生存获益更明显。
- 结果支持在严格筛选的无症状重度AS患者中早期行SAVR。
核心结论
- 在重度AS且LVEF≥50%患者中,症状出现前行SAVR显示更优的长期生存。
- 研究支持在严格筛选的无症状重度AS患者中早期行SAVR。
研究设计与样本
- 队列链接CMS数据,主要结局为风险调整后10年生存,并按年龄、LVEF和STS PROM进行亚组分析。
主要发现
- 共17,683例LVEF≥50%行孤立SAVR患者,其中16,284例(92.1%)有症状,1,399例(7.9%)无症状。
- 无症状组较有症状组更年轻(平均年龄74.2 vs 75.0岁,P<.001),STS PROM更低(1.9%±1.4% vs 2.5%±2.0%,P<.001)。
- 风险调整后无症状组10年生存优于有症状组(aHR 1.19,95%CI 1.09-1.29)。
- 亚组中年龄≥75岁(aHR 1.24,95%CI 1.11-1.39)、LVEF≥60%(aHR 1.20,95%CI 1.08-1.34)、STS PROM<2%(aHR 1.17,95%CI 1.01-1.34)的无症状vs有症状长期生存获益更明显。
关键数值与推荐
- 无症状组与有症状组风险调整后10年生存aHR为1.19(95%CI 1.09-1.29)。
- 年龄≥75岁亚组aHR为1.24(95%CI 1.11-1.39)。
- LVEF≥60%亚组aHR为1.20(95%CI 1.08-1.34)。
- STS PROM<2%亚组aHR为1.17(95%CI 1.01-1.34)。
临床怎么用
- 对无症状重度AS且LVEF≥50%患者,尤其年龄≥75岁、LVEF≥60%或STS PROM<2%者,可考虑早期SAVR以改善长期生存。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recent evidence supports early intervention in patients with asymptomatic aortic stenosis (AS) and normal ejection fraction. The study objective was to compare longitudinal surgical aortic valve replacement (SAVR) outcomes in asymptomatic vs symptomatic patients with normal left ventricular ejection fraction (LVEF). METHODS: The Society of Thoracic Surgeons (STS) Adult Cardiac Surgery Database was leveraged to identify patients who underwent isolated SAVR for asymptomatic or symptomatic severe AS with LVEF ≥50% between July 2011 and December 2022. The cohort was linked to Centers for Medicare & Medicaid Services data. The primary outcome was risk-adjusted 10-year survival. Subgroup analysis evaluated long-term survival stratified by age, LVEF, and STS predicted risk of mortality (PROM). RESULTS: A total of 17,683 patients with LVEF ≥50% underwent isolated SAVR; 16,284 (92.1%) were symptomatic and 1399 (7.9%) were asymptomatic. Compared with symptomatic patients, asymptomatic patients were younger (mean age, 74.2 vs 75.0 years; P < .001) and had lower STS PROM (1.9% ± 1.4% vs 2.5% ± 2.0%; P < .001). After risk adjustment, asymptomatic patients demonstrated superior 10-year survival compared with symptomatic patients (adjusted hazard ratio [aHR], 1.19 [95% CI, 1.09-1.29]). In subgroup analyses, long-term survival benefit was more pronounced in asymptomatic vs symptomatic patients aged ≥75 years (aHR, 1.24 [95% CI, 1.11-1.39]), LVEF ≥60% (aHR, 1.20 [95% CI, 1.08-1.34]), and STS PROM <2% (aHR, 1.17 [95% CI, 1.01-1.34]). CONCLUSIONS: In patients with severe AS and preserved LVEF, SAVR before symptom onset shows superior long-term survival. This study supports early SAVR in carefully selected patients with asymptomatic severe AS.
引用
- Braasch MC, Bonnell L, Siki MA, et al. Longitudinal Surgical Aortic Valve Replacement Outcomes for Asymptomatic Severe Aortic Stenosis With Preserved Ejection Fraction. Ann Thorac Surg. 2026. PMID: 42119755. doi:10.1016/j.athoracsur.2026.04.047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。